Trial Profile
Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs TJ 9 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 09 Jun 2014 New trial record